Business Wire

Westlake Announces Proposed Offering of Senior Notes

Share

Westlake Corporation (NYSE: WLK) (“Westlake”) announced today the commencement of an underwritten public offering, subject to market and other conditions, of senior unsecured notes (the “Notes”) under its existing shelf registration statement.

The timing of pricing and terms of the Notes are subject to market conditions and other factors. Westlake intends to use the net proceeds from the proposed public offering of the Notes to fund the repurchase of its outstanding 3.600% Senior Notes due 2026 (the “2026 Senior Notes”) pursuant to a concurrent cash tender offer (the “Tender Offer”) for any and all of the 2026 Senior Notes. Westlake anticipates using any remaining net proceeds to fund the purchase price of its pending acquisition of the global compounding solutions businesses of the ACI/Perplastic Group (the “ACI Acquisition”) and for general corporate purposes, including working capital management. The offering of the Notes is not contingent upon the successful completion of the Tender Offer or the consummation of the ACI Acquisition.

The Notes are being offered and will be sold only pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities (including the Notes), nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. The offering of the Notes is being made only by means of a prospectus and related prospectus supplement meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

This press release shall not constitute an offer to purchase or a solicitation of an offer to sell any of the 2026 Senior Notes. The Tender Offer is being made only by and pursuant to, and on the terms and conditions set forth in, the Offer to Purchase dated November 4, 2025.

BofA Securities, Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering of the Notes. A copy of the preliminary prospectus supplement and accompanying base prospectus relating to the offering of the Notes may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov or by making a request to: BofA Securities, Inc. at 1-800-294-1322; Deutsche Bank Securities Inc. at 1-800-503-4611; J.P. Morgan Securities LLC collect at 1-212-834-4533; or Wells Fargo Securities, LLC at 1-800-645-3751.

About Westlake

Westlake is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe and North America, Westlake provides the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer goods.

Forward-Looking Statements

The statements in this press release that are not historical facts, such as statements regarding the proposed public offering of the Notes and the use of proceeds therefrom and other matters relating to the proposed public offering, are forward-looking statements that are based on current expectations. Although Westlake believes that its expectations are based on reasonable assumptions, it can give no assurance that these expectations will prove correct. Important factors that could cause actual results to differ materially from those in the forward-looking statements include results of operations, market conditions, capital needs and uses and other risks and uncertainties that are beyond Westlake’s control, including those described in the preliminary prospectus supplement and accompanying base prospectus relating to the offering of the Notes, Westlake’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, Westlake’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025 and September 30, 2025 and its other filings with the SEC. Forward-looking statements, like all statements in this press release, speak only as of the date of this press release (unless another date is indicated). Westlake does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251103367398/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ClickHouse Acquires LibreChat to Democratize AI-Driven Analytics Through the Open-Source Agentic Data Stack4.11.2025 18:00:00 CET | Press release

ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytics database, today announced the acquisition of LibreChat, a leading open-source AI chat platform that provides a unified interface for interacting with large language models (LLMs). The acquisition brings LibreChat founder Danny Avila and his team to ClickHouse. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104505230/en/ ClickHouse acquires LibreChat: Introducing the open-source Agentic Data Stack Together, ClickHouse and LibreChat form the foundation of the open-source Agentic Data Stack, empowering teams to deploy AI agents that analyze and act on large datasets through natural language. This shift to agentic analytics is already transforming how organizations such as Shopify, Daimler Truck, Fetch, and cBioPortal leverage their data, demonstrating the immediate value in real-world applications. At Shopify, LibreChat has become c

Mouser Electronics Explores the Future of Advanced Air Mobility and Its Impact on Design4.11.2025 17:37:00 CET | Press release

Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, released its latest installment of the Empowering Innovation Together (EIT) technology series, Urban Transport Takes Flight, examining the emerging sector of Advanced Air Mobility (AAM). This series details the technology behind electric vertical takeoff and landing (eVTOL) vehicles, the challenges of infrastructure for city deployment, and the hydrogen fuel cell solutions that power the future of urban transport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104083206/en/ Mouser explores the technology behind urban air mobility (UAM) vehicles, the challenges of infrastructure, and the fuel solutions that are powering the future of urban transport. The path for Urban Air Mobility (UAM) to transition from futuristic concept to scalable reality is constrained by barriers in form, power, and

Sparkle Clean Tech and Aquadei Launch Global Alliance to Transform Oil & Gas Water Treatment with Next-Gen Nanobubble Technology4.11.2025 17:02:00 CET | Press release

Sparkle Clean Tech (SCT)(exclusive global licensee of Siemens Energy’s oil & gas water-treatment IP) and Aquadei, LLC have formed a strategic alliance to deploy Aquadei’s proprietary nanobubble and hydrodynamic cavitation technologies to oil & gas operations globally. This partnership is set to drive advanced water treatment methods, delivering measurable operational, economic and environmental benefits across the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104652683/en/ Nanobubble Technology in Oil & Gas: Performance Advantages Nanobubbles (gas particles smaller than 200 nanometers) feature extraordinary physical surface and interfacial properties that enhance how oil and solids interact in water. When paired with SCT’s separation technologies, these ultrafine bubbles enable more efficient separation, lower chemical consumption, and greater process stability. Unlike traditional flotation systems that rely on

GD32 MCU Family Expands High-Performance Portfolio with New GD32F503/505 Series MCU4.11.2025 17:00:00 CET | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced the official launch of the GD32F503/505 high-performance series of 32-bit general-purpose microcontrollers. This release significantly strengthens its product portfolio based on the Arm® Cortex®-M33 core. Built on the Arm® v8-M architecture, the series operates at a frequency of 280 MHz and features flexible memory configurations and built-in security functions. It is well-suited for a wide range of applications, including digital power supplies, industrial automation, motor control, robotic vacuum cleaners, BMS, humanoid robots, and more. The GD32F503/505 series MCUs are now available as samples and development boards are available on request, with mass production due to begin in December. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104783233/en/ Higher Frequency for S

Zetagen Therapeutics to Present Promising Preclinical Data at SABCS: Zeta-BC-007 Demonstrates Superior Tumoricidal Activity and Survival Benefit in Breast Cancer Model4.11.2025 16:48:00 CET | Press release

Survival Advantage: Mice treated with Zeta-BC-007 survived beyond 60 days, unlike those receiving Tamoxifen (TAM) or Abemaciclib (ABE)Tumor Reduction: Zeta-BC-007 combinations reduced tumor volume by up to 66%, compared to 34% (TAM) and 15% (ABE)Synergistic Cytotoxicity: NaN and ABE together decreased cell proliferation by 60% in vitro, suggesting synergistic effectsNo Tumor Activity: Histology revealed no ki67 staining and increased necrosis in Zeta-BC-007-treated tumorsImmune Activation: Treated mice showed elevated macrophage infiltration and increased circulating monocytes Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its abstract titled “Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye